Prelude Therapeutics EVP/Chief of Clinical Affairs Morosini resigns; advisor through May 5

Prelude Therapeutics Inc

Deborah Morosini resigned as EVP and Chief of Clinical Affairs effective April 6, 2022.
She will serve as Strategic Advisor to the President until May 5, 2022, then employment ends.
Severance includes 3 months base salary and 3 months COBRA premium payments.
She may provide consulting services from May 5 to November 4, 2022 on an as-needed basis.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Deborah Morosini

EVP and Chief of Clinical Affairs

PRLD · Prelude Therapeutics Inc

Effective: 2022-04-06
Filed: April 8, 2022, 7:59 PM ET

On April 6, 2022 (the “ Effective Date ”), Prelude Therapeutics Incorporated (the “ Company ”) and Deborah Morosini, the Company’s EVP and Chief of Clinical Affairs, agreed that, effective as of the Effective Date, Dr. Morosini shall resign from her role as an officer of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Deborah Morosini resigned as EVP and Chief of Clinical Affairs at Prelude Therapeutics Inc.

Action: resigned
Role: EVP and Chief of Clinical Affairs

Exact text from the filing

On April 6, 2022 (the “ Effective Date ”), Prelude Therapeutics Incorporated (the “ Company ”) and Deborah Morosini, the Company’s EVP and Chief of Clinical Affairs, agreed that, effective as of the Effective Date, Dr. Morosini shall resign from her role as an officer of the Company

View on SEC.gov

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0001193125-22-100388

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.